title: [A case of poorly differentiated adenocarcinoma of the uterine cervix treated with paclitaxel and carboplatin after positive PAX 8 immunostaining].
abstract: PAX 8 is a paired-box gene that plays an important role in the embryogenesis of the thyroid gland, Müllerian ducts, and renal/upper urinary tract. PAX 8 expression is observed in carcinomas from each of these sites. Accordingly, PAX 8 immunostaining has been reported to be useful for the diagnosis of these carcinomas. Here, we report a case in which PAX 8 was useful for the diagnosis of a patient with cervical adenocarcinoma and multiple metastases. A 55-year-old female patient complained of cough and genital bleeding. Examination revealed a uterine cervical mass, masses in both breasts, and enlargement of the lymph nodes and subcutaneous nodules. Histology of the uterine cervical mass biopsy revealed a poorly differentiated adenocarcinoma. Cytology of the aspiration biopsy specimens of the breast masses indicated scirrhous cancer. PAX 8 immunostaining of the uterine cervical mass and breast mass biopsies was positive. We determined that the breast masses were metastases of the cervical adenocarcinoma and decided to treat the patient with chemotherapy consisting of paclitaxel and carboplatin. A partial response was observed. A hysterectomy was performed 5 months after chemotherapy because corpus cancer was newly diagnosed. The cervical adenocarcinoma was undetectable in the surgical specimen. Fifteen months have passed since the completion of chemotherapy and the metastases has been under control.
authors.affiliation: Dept. of Obstetrics and Gynecology, Osaka Police Hospital.
authors.forename: Takahide
authors.initials: T
authors.lastname: Maenaka
authors.forename: Noriko
authors.initials: N
authors.lastname: Iwata
authors.forename: Tomomi
authors.initials: T
authors.lastname: Egawa-Takata
authors.forename: Yayoi
authors.initials: Y
authors.lastname: Fukuda
authors.forename: Chikako
authors.initials: C
authors.lastname: Tsukahara
authors.forename: Hiromi
authors.initials: H
authors.lastname: Kashihara
authors.forename: Koji
authors.initials: K
authors.lastname: Hisamoto
authors.forename: Ichiro
authors.initials: I
authors.lastname: Kunishige
authors.forename: Yukihiro
authors.initials: Y
authors.lastname: Nishio
authors.forename: Masahiko
authors.initials: M
authors.lastname: Tsujimoto
mesh_terms: D000230:Adenocarcinoma / Q000737:chemistry / Q000188:drug therapy*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D000072636:PAX8 Transcription Factor; D017239:Paclitaxel / Q000008:administration & dosage; D051761:Paired Box Transcription Factors / Q000032:analysis; D002583:Uterine Cervical Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000072636:PAX8 Transcription Factor; C083325:PAX8 protein, human; D051761:Paired Box Transcription Factors; D016190:Carboplatin; D017239:Paclitaxel